Q1 EPS Estimate for Sage Therapeutics Raised by Analyst

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Research analysts at Wedbush lifted their Q1 2025 EPS estimates for Sage Therapeutics in a research report issued to clients and investors on Wednesday, April 16th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings per share of ($1.17) for the quarter, up from their previous estimate of ($1.24). Wedbush has a “Neutral” rating and a $6.00 price objective on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($3.52) per share. Wedbush also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($0.99) EPS, FY2025 earnings at ($4.15) EPS, FY2026 earnings at ($2.80) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.22) EPS and FY2029 earnings at ($0.90) EPS.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%.

Several other equities research analysts also recently issued reports on the stock. Bank of America began coverage on shares of Sage Therapeutics in a research report on Tuesday, March 11th. They set an “underperform” rating and a $5.00 price objective for the company. Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, February 12th. HC Wainwright restated a “neutral” rating and issued a $12.00 price target (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Canaccord Genuity Group decreased their price objective on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday, February 12th. Finally, Scotiabank dropped their target price on Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, February 12th. Three research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $8.81.

Sage Therapeutics Stock Performance

Shares of SAGE stock opened at $7.43 on Friday. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $14.97. The company’s 50 day moving average price is $7.47 and its two-hundred day moving average price is $6.72. The company has a market capitalization of $456.80 million, a P/E ratio of -1.13 and a beta of 0.48.

Institutional Trading of Sage Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SAGE. Picton Mahoney Asset Management boosted its stake in shares of Sage Therapeutics by 126.0% during the 4th quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 3,581 shares during the period. KLP Kapitalforvaltning AS bought a new position in Sage Therapeutics during the fourth quarter worth $49,000. Ieq Capital LLC acquired a new position in shares of Sage Therapeutics in the fourth quarter valued at $57,000. GAMMA Investing LLC raised its position in shares of Sage Therapeutics by 16,118.0% in the first quarter. GAMMA Investing LLC now owns 8,109 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 8,059 shares during the period. Finally, US Bancorp DE lifted its stake in shares of Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 2,268 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.